{"analyses":[{"ciLowerLimit":"0.268","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.561","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Two-sided P-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.39","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.2","upperLimit":"23.3","value":"20.0"},{"groupId":"OG001","lowerLimit":"7.9","upperLimit":"10.4","value":"9.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.","id":"OG000","title":"gBRCA Niraparib"},{"description":"Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.","id":"OG001","title":"gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat Population","reportingStatus":"POSTED","timeFrame":"From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days","title":"Chemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA)","type":"SECONDARY","unitOfMeasure":"Months"}